158 related articles for article (PubMed ID: 9563898)
1. Activity of oxaliplatin against human tumor colony-forming units.
Raymond E; Lawrence R; Izbicka E; Faivre S; Von Hoff DD
Clin Cancer Res; 1998 Apr; 4(4):1021-9. PubMed ID: 9563898
[TBL] [Abstract][Full Text] [Related]
2. Oxaliplatin induces drug resistance more rapidly than cisplatin in H69 small cell lung cancer cells.
Stordal BK; Davey MW; Davey RA
Cancer Chemother Pharmacol; 2006 Aug; 58(2):256-65. PubMed ID: 16283310
[TBL] [Abstract][Full Text] [Related]
3. Antitumor activity of a new platinum compound (glycolate-o,o') diammineplatinum (II) (254-S), against non-small cell lung carcinoma grown in a human tumor clonogenic assay system.
Kanzawa F; Matsushima Y; Nakano H; Nakagawa K; Takahashi H; Sasaki Y; Saijo N
Anticancer Res; 1988; 8(3):323-7. PubMed ID: 2839098
[TBL] [Abstract][Full Text] [Related]
4. In vitro phase II comparison of the cytotoxicity of a novel platinum analog, nedaplatin (254-S), with that of cisplatin and carboplatin against fresh, human cervical cancers.
Monk BJ; Alberts DS; Burger RA; Fanta PT; Hallum AV; Hatch KD; Salmon SE
Gynecol Oncol; 1998 Nov; 71(2):308-12. PubMed ID: 9826477
[TBL] [Abstract][Full Text] [Related]
5. In vitro cytotoxicity of hepsulfam against human tumor cell lines and primary human tumor colony forming units.
Marshall MV; Marshall MH; Degen DR; Roodman GD; Kuhn JG; Ross ME; Von Hoff DD
Stem Cells; 1993 Jan; 11(1):62-9. PubMed ID: 8457783
[TBL] [Abstract][Full Text] [Related]
6. Differential cytotoxic activity of chemotherapy agents on colony-forming cells from human tumors and normal bone marrow in vitro.
Ajani JA; Blaauw AA; Spitzer G; Baker FL; Tomasovic B; Umbach G; Thielvoldt D; Zander AR; Dicke KA
Exp Hematol; 1985; 13 Suppl 16():95-100. PubMed ID: 2580731
[TBL] [Abstract][Full Text] [Related]
7. Oxaliplatin in treatment of the cisplatin-resistant MKN45 cell line of gastric cancer.
Tozawa K; Oshima T; Kobayashi T; Yamamoto N; Hayashi C; Matsumoto T; Miwa H
Anticancer Res; 2008; 28(4B):2087-92. PubMed ID: 18751380
[TBL] [Abstract][Full Text] [Related]
8. In vitro cytotoxicity, protein binding, red blood cell partitioning, and biotransformation of oxaliplatin.
Pendyala L; Creaven PJ
Cancer Res; 1993 Dec; 53(24):5970-6. PubMed ID: 8261411
[TBL] [Abstract][Full Text] [Related]
9. Oxaliplatin exerts potent in vitro cytotoxicity in colorectal and pancreatic cancer cell lines and liver metastases.
Kornmann M; Fakler H; Butzer U; Beger HG; Link KH
Anticancer Res; 2000; 20(5A):3259-64. PubMed ID: 11062751
[TBL] [Abstract][Full Text] [Related]
10. Exposure-response relationships for oxaliplatin-treated colon cancer cells.
Kirstein MN; Root SA; Moore MM; Wieman KM; Williams BW; Jacobson PA; Marker PH; Tuttle TM
Anticancer Drugs; 2008 Jan; 19(1):37-44. PubMed ID: 18043128
[TBL] [Abstract][Full Text] [Related]
11. Novel mechanisms of platinum drug resistance identified in cells selected for resistance to JM118 the active metabolite of satraplatin.
Samimi G; Kishimoto S; Manorek G; Breaux JK; Howell SB
Cancer Chemother Pharmacol; 2007 Feb; 59(3):301-12. PubMed ID: 16770583
[TBL] [Abstract][Full Text] [Related]
12. cis-Amminedichloro(2-methylpyridine) platinum(II) (AMD473), a novel sterically hindered platinum complex: in vivo activity, toxicology, and pharmacokinetics in mice.
Raynaud FI; Boxall FE; Goddard PM; Valenti M; Jones M; Murrer BA; Abrams M; Kelland LR
Clin Cancer Res; 1997 Nov; 3(11):2063-74. PubMed ID: 9815598
[TBL] [Abstract][Full Text] [Related]
13. Antitumor activity of a new platinum(II) complex with low nephrotoxicity and genotoxicity.
Marzano C; Bettio F; Baccichetti F; Trevisan A; Giovagnini L; Fregona D
Chem Biol Interact; 2004 Jun; 148(1-2):37-48. PubMed ID: 15223355
[TBL] [Abstract][Full Text] [Related]
14. Oxaliplatin: mechanism of action and antineoplastic activity.
Raymond E; Faivre S; Woynarowski JM; Chaney SG
Semin Oncol; 1998 Apr; 25(2 Suppl 5):4-12. PubMed ID: 9609103
[TBL] [Abstract][Full Text] [Related]
15. Identification of non-cross-resistant platinum compounds with novel cytotoxicity profiles using the NCI anticancer drug screen and clustered image map visualizations.
Fojo T; Farrell N; Ortuzar W; Tanimura H; Weinstein J; Myers TG
Crit Rev Oncol Hematol; 2005 Jan; 53(1):25-34. PubMed ID: 15607933
[TBL] [Abstract][Full Text] [Related]
16. Combination of cyclooxygenase-2 inhibitors and oxaliplatin increases the growth inhibition and death in human colon cancer cells.
Lin J; Hsiao PW; Chiu TH; Chao JI
Biochem Pharmacol; 2005 Sep; 70(5):658-67. PubMed ID: 16004971
[TBL] [Abstract][Full Text] [Related]
17. Preclinical antitumor activity of the oral platinum analog satraplatin.
Wosikowski K; Lamphere L; Unteregger G; Jung V; Kaplan F; Xu JP; Rattel B; Caligiuri M
Cancer Chemother Pharmacol; 2007 Sep; 60(4):589-600. PubMed ID: 17541592
[TBL] [Abstract][Full Text] [Related]
18. Oxaliplatin activity in head and neck cancer cell lines.
Espinosa M; Martinez M; Aguilar JL; Mota A; De la Garza JG; Maldonado V; Meléndez-Zajgla J
Cancer Chemother Pharmacol; 2005 Mar; 55(3):301-5. PubMed ID: 15619139
[TBL] [Abstract][Full Text] [Related]
19. A murine model to evaluate the ability of in vitro clonogenic assays to predict the response to tumors in vivo.
Mirabelli CK; Sung CM; McCabe FL; Faucette LF; Crooke ST; Johnson RK
Cancer Res; 1988 Oct; 48(19):5447-54. PubMed ID: 3046738
[TBL] [Abstract][Full Text] [Related]
20. Oxaliplatin activity in selected and unselected human ovarian and colorectal cancer cell lines.
Noordhuis P; Laan AC; van de Born K; Losekoot N; Kathmann I; Peters GJ
Biochem Pharmacol; 2008 Jul; 76(1):53-61. PubMed ID: 18508032
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
